This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116540648/en/

With its physics-based generative AI platform for therapeutic molecule invention, QEMI, Aqemia can design novel drug candidates in a repeatable, frugal, and scalable way, with the ambition to deliver new therapies faster to patients who currently lack effective treatments, particularly in oncology. In this perspective, Aqemia remains focused on building value through its internal preclinical pipeline while forging partnerships that validate its platform and scientific edge.

About Aqemia

Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI platform combines more than 12 years of physics-based research with state-of-the-art generative AI, enabling the launch of preclinical programs without relying on experimental data and accelerating discovery from day one. Aqemia's portfolio spans oncology, immunology, neurology, and cardiology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, $150M strategic collaboration with Sanofi. The company's most advanced preclinical programs are currently undergoing in vivo optimization. Headquartered in Paris with an office in London, Aqemia has raised over $100 million since its inception.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251116540648/en/

Contact

PressOrianne Bornand - Head of Communications+33 6 10 04 32 80 I [email protected]

© 2025 Business Wire, Inc.Disclaimer:This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.